POPULARITY
11 episodes with inhbitor
4 episodes with inhbitor
6 episodes with inhbitor
Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.
Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.
Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.
Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.
Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
Dr. Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, details the positive trial results for immunotherapy in a wide variety of cancers. He also describes current trials of combination regimens and the future of immunotherapy.
Dr. Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, details the positive trial results for immunotherapy in a wide variety of cancers. He also describes current trials of combination regimens and the future of immunotherapy.
Dr. Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, details the positive trial results for immunotherapy in a wide variety of cancers. He also describes current trials of combination regimens and the future of immunotherapy.
Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.
Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.
Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.
© 2020-2025 Ivy Podcast Discovery LLC
